Company Description
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications.
The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure.
The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
| Country | WA |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Jacob P. Lalezari M.D. |
Contact Details
Address: 1111 Main Street, Suite 660 Vancouver, Washington 98660 United States | |
| Phone | 360-980-8524 |
| Website | cytodyn.com |
Stock Details
| Ticker Symbol | CYDY |
| Exchange | OTCMKTS |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001175680 |
| CUSIP Number | 23283M101 |
| ISIN Number | US23283M1018 |
| Employer ID | 75-3056237 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cyrus Arman M.B.A., Ph.D. | Senior Vice President of Business Operations |
| Dr. Jacob P. Lalezari M.D. | Chief Executive Officer and Member of Scientific Advisory Board |
| Mitchell Cohen | Interim Chief Financial Officer |
| Tyler Blok | Executive Vice President of Legal Affairs and Secretary |
| Dr. Scott Hansen Ph.D. | Head of Research and Basic Science |
| Joseph Meidling | Executive Director of Clinical Operations |
| Cristina De Leon | Investors |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 424B3 | Prospectus |
| Apr 16, 2024 | 424B3 | Prospectus |
| Apr 15, 2024 | 10-Q | Quarterly Report |
| Apr 8, 2024 | 424B3 | Prospectus |
| Apr 8, 2024 | 424B3 | Prospectus |
| Apr 8, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 424B3 | Prospectus |
| Mar 1, 2024 | 424B3 | Prospectus |
| Feb 22, 2024 | 424B3 | Prospectus |